Skip to main content

Advertisement

Table 1 Relative serious infectious event risk associated with baseline age categories and medically treated comorbidities included in age-adjusted comorbidity index

From: Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

  HR (95% CI) Weight in the AACIa
Category RCT CZP (n = 1224) All CZP (n = 1506)
Age, years <50 Reference Reference 0
≥50 to < 60 1.29 (0.58–2.87) 1.39 (0.99–1.96) 1
≥60 to < 70 1.14 (0.44–2.94) 1.40 (0.92–2.12) 1
≥70 2.18 (0.70–6.84) 2.93 (1.69–5.09) 3
Diabetes mellitus 1.98 (0.59–6.58) 1.61 (0.90–2.89) 2
COPD/asthma 2.67 (0.77–9.27) 1.29 (0.56–2.97) 2
Cardiac disorder N/C 1.33 (0.52–3.43) 0
Hypertension 1.34 (0.69–2.63) 0.96 (0.70–1.32) 0
Hyperlipidemia 2.39 (0.82–6.93) 1.47 (0.81–2.67) 2
Thyroid disorder N/C 0.87 (0.42–1.78) 0
Osteoporosis 2.30 (0.98–5.39) 1.16 (0.73–1.86) 2
Depression 1.00 (0.22–4.51) 1.46 (0.75–2.83) 1
  1. Abbreviations: SIE Serious infectious event, AACI Age-adjusted comorbidity index, CZP Certolizumab pegol, COPD Chronic obstructive pulmonary disease, N/C Not calculable (no patients with the indicated comorbidity experienced an SIE during the randomized controlled trials), RCT CZP Patients randomized to CZP in the RAPID1/RAPID2 randomized controlled trials, All CZP All patients treated with CZP during the RAPID1/RAPID2 randomized controlled trials and/or open label extensions
  2. HRs were derived from a Cox proportional hazards model fitted with the indicated age categories and medically treated comorbidities; no other baseline covariates were included
  3. aWeight of each category in the AACI was based on the average HR between the RCT CZP and All CZP populations (HR ≥ 1.2 and < 1.5, weight = 1; HR ≥ 1.5 and < 2.5, weight = 2; HR ≥ 2.5 and < 3.5, weight = 3)